EXAS - イグザクト・サイエンシズ (Exact Sciences Corporation) イグザクト・サイエンシズ

 EXASのチャート


 EXASの企業情報

symbol EXAS
会社名 EXACT Sciences Corp. (イグザクト・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イグザクト・サイエンシズ(Exact Sciences Corporation)は分子診断会社である。同社は癌の早期発見および予防に焦点を当てている。同社は結腸直腸癌および前癌の早期発見のためのCologuardと呼ばれる非侵襲的スクリーニング試験を提供する。コングルード試験はデオキシリボ核酸(DNA)および結腸直腸癌および前癌に関連するヘモグロビンバイオマーカーを検出するための多標的アプローチを利用する便ベースのデオキシリボ核酸(sDNA)スクリーニング試験である。コルグアード試験は、結腸直腸新生物に関連するDNAマーカーの定性的検出およびヒトの便における潜在性ヘモグロビンの存在を目的としている。同社は他のタイプの癌に対する追加試験の開発に焦点を当てる。同社はコンピュータ断層撮影(CT)または他のスキャンによって発見された肺結節を有する個体において、肺癌の早期発見を助けるための血液ベースのバイオマーカー試験を開発している。   イグザクト・サイエンシズは米国の癌検出製品メ―カ―。大腸癌および前癌状態の早期発見と予防に焦点を当て、非侵襲性スクリ―ニングテスト製品を開発。排便からDNAを検出し大腸癌に関わる遺伝子から癌を見つけ出す製品「Cologuard」を提供。同製品は前癌病変やポリ―プ、および大腸癌の4段階の進行度を検出する。   
本社所在地 441 Charmany Drive Madison WI 53719 USA
代表者氏名 Kevin T. Conroy ケヴィン・T・コンローイ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 608-284-5700
設立年月日 34731
市場名 NASDAQ Small Cap
ipoyear 2001年
従業員数 1268人
url www.exactsciences.com
nasdaq_url https://www.nasdaq.com/symbol/exas
adr_tso
EBITDA EBITDA(百万ドル) -102.08500
終値(lastsale) 68.46
時価総額(marketcap) 8403727817.94
時価総額 時価総額(百万ドル) 8597.679
売上高 売上高(百万ドル) 353.17000
企業価値(EV) 企業価値(EV)(百万ドル) 828.906
当期純利益 当期純利益(百万ドル) -249.37200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 EXACT Sciences Corporation revenues increased 82% to $193.2M. Net loss applicable to common stockholders increased 15% to $75.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 38% to $55.1M (expense) Interest expense increase from $104K to $15.1M (expense).

 EXASのテクニカル分析


 EXASのニュース

   Exact Sciences Drops on Earnings Loss, Lack of Visibility  2021/02/17 18:00:28 The Street
Exact Sciences swung to a large fourth quarter loss due in part to its purchase of Base Genomics.
   Exact Sciences Announces Fourth Quarter 2020 Results  2021/02/16 21:05:00 PR Newswire
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. "Exact Sciences finished another…
   Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com  2021/01/21 16:35:00 Investing.com
Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp.
   Cologuard accurately screens younger individuals for colorectal cancer  2021/01/15 18:00:00 BioWorld
The U.S. Preventive Services Task Force (USPSTF) appears on the verge of expanding colorectal cancer screening to individuals ages 45 to 49, based on its latest draft recommendations. If it does, Exact Sciences Corp. is ready. A study in Cancer Prevention Research demonstrated that the Madison, Wis.-based company's Cologuard multitarget stool DNA test had better than 95% specificity in individuals with nonadvanced precancerous lesions or negative findings on colonoscopy.
   Exact Sciences to participate in December investor conference  2020/11/23 11:00:00 PR Newswire
MADISON, Wis., Nov. 23, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast. Evercore ISI HealthCONx Conference Fireside Chat on Wednesday, December 2,…
   Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com  2021/01/21 16:35:00 Investing.com
Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp.
   Cologuard accurately screens younger individuals for colorectal cancer  2021/01/15 18:00:00 BioWorld
The U.S. Preventive Services Task Force (USPSTF) appears on the verge of expanding colorectal cancer screening to individuals ages 45 to 49, based on its latest draft recommendations. If it does, Exact Sciences Corp. is ready. A study in Cancer Prevention Research demonstrated that the Madison, Wis.-based company's Cologuard multitarget stool DNA test had better than 95% specificity in individuals with nonadvanced precancerous lesions or negative findings on colonoscopy.
   Exact Sciences to participate in December investor conference  2020/11/23 11:00:00 PR Newswire
MADISON, Wis., Nov. 23, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast. Evercore ISI HealthCONx Conference Fireside Chat on Wednesday, December 2,…
   Global In-Vitro Colorectal Cancer Screening Tests Market Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027|| Clinical Genomics Technologies Pty, Ltd, Epigenomics Inc, Hemosure, Inc, Exact Sciences Corporation, NOVIGEN  2020/11/12 13:42:48 OpenPR
Data Bridge Market research presents the top quality and comprehensive In-Vitro Colorectal Cancer Screening Tests research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This
   Cancer Biomarkers Market 2020 - 2027 Global Size, Share, Industry Key Players like Abbott Laboratories, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Exact Sciences  2020/11/05 17:01:37 OpenPR
According to the report, the global cancer biomarkers industry was estimated at $10.94 billion in 2019, and is expected to hit $26.97 billion by 2027, registering a CAGR of 11.8% from 2020 to 2027. Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1443 Surge in number
   Cologuard accurately screens younger individuals for colorectal cancer  2021/01/15 18:00:00 BioWorld
The U.S. Preventive Services Task Force (USPSTF) appears on the verge of expanding colorectal cancer screening to individuals ages 45 to 49, based on its latest draft recommendations. If it does, Exact Sciences Corp. is ready. A study in Cancer Prevention Research demonstrated that the Madison, Wis.-based company's Cologuard multitarget stool DNA test had better than 95% specificity in individuals with nonadvanced precancerous lesions or negative findings on colonoscopy.
   Exact Sciences to participate in December investor conference  2020/11/23 11:00:00 PR Newswire
MADISON, Wis., Nov. 23, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast. Evercore ISI HealthCONx Conference Fireside Chat on Wednesday, December 2,…
   Global In-Vitro Colorectal Cancer Screening Tests Market Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027|| Clinical Genomics Technologies Pty, Ltd, Epigenomics Inc, Hemosure, Inc, Exact Sciences Corporation, NOVIGEN  2020/11/12 13:42:48 OpenPR
Data Bridge Market research presents the top quality and comprehensive In-Vitro Colorectal Cancer Screening Tests research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This
   Cancer Biomarkers Market 2020 - 2027 Global Size, Share, Industry Key Players like Abbott Laboratories, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Exact Sciences  2020/11/05 17:01:37 OpenPR
According to the report, the global cancer biomarkers industry was estimated at $10.94 billion in 2019, and is expected to hit $26.97 billion by 2027, registering a CAGR of 11.8% from 2020 to 2027. Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1443 Surge in number
   Rapid Cancer Tests Market 2020 Precise Outlook – Abingdon Health, Hologic, Abbott, NanoEntek, Biomerica, Alfa Scientific Designs, Exact Sciences, Biosynex  2020/11/03 08:10:09 OpenPR
The Rapid Cancer Tests Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イグザクト・サイエンシズ EXAS Exact Sciences Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)